Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
Nippon Shinyaku said on December 20 that it has won orphan drug designation from the US FDA for its oral selective JAK2 inhibitor ilginatinib (NS-018), which is now being developed for the treatment of myelofibrosis. The Japanese company is currently…
To read the full story
Related Article
- Nippon Shinyaku Gets EU Orphan Tag for Myelofibrosis Med
August 9, 2023
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…